Abstract
Over the last two decades, SPECT (single photon emission computed tomography) and especially PET (positron emission tomography) have proven increasingly effective imaging modalities in the study of human psychopharmacology. Abusing populations can be studied at multiple times after abstinence begins, to give information about neurochemical and physiological adaptations of the brain during recovery from addiction. Individual human subjects can be studied using multiple positron labeled radiotracers, so as to probe more than one facet of brain function. PET and SPECT have been used to help our understanding of many aspects of the pharmacokinetics and pharmacodynamics of abused drugs, and have made valuable contributions in terms of drug mechanisms, drug interactions (e.g. cocaine and alcohol) and drug toxicities. They have also been employed to study the acute effects of drugs on populations of active drug abusers and of normal controls, and to evaluate the neurochemical consequences of candidate therapies for drug abuse. A particularly productive strategy has been the use of PET in conjunction with neuropsychological testing of subjects, to allow correlation of imaging data with uniquely human aspects of the effects of drugs, such as euphoria and craving.
Keywords: human imaging, radiotracer, alcoholism, radiopharmaceutical, drug clearance, labeled drug, opioids
Current Pharmaceutical Design
Title: PET Imaging in Clinical Drug Abuse Research
Volume: 11 Issue: 25
Author(s): S. J. Gatley, N. D. Volkow, G.- J. Wang, J. S. Fowler, J. Logan, Y.- S. Ding and M. Gerasimov
Affiliation:
Keywords: human imaging, radiotracer, alcoholism, radiopharmaceutical, drug clearance, labeled drug, opioids
Abstract: Over the last two decades, SPECT (single photon emission computed tomography) and especially PET (positron emission tomography) have proven increasingly effective imaging modalities in the study of human psychopharmacology. Abusing populations can be studied at multiple times after abstinence begins, to give information about neurochemical and physiological adaptations of the brain during recovery from addiction. Individual human subjects can be studied using multiple positron labeled radiotracers, so as to probe more than one facet of brain function. PET and SPECT have been used to help our understanding of many aspects of the pharmacokinetics and pharmacodynamics of abused drugs, and have made valuable contributions in terms of drug mechanisms, drug interactions (e.g. cocaine and alcohol) and drug toxicities. They have also been employed to study the acute effects of drugs on populations of active drug abusers and of normal controls, and to evaluate the neurochemical consequences of candidate therapies for drug abuse. A particularly productive strategy has been the use of PET in conjunction with neuropsychological testing of subjects, to allow correlation of imaging data with uniquely human aspects of the effects of drugs, such as euphoria and craving.
Export Options
About this article
Cite this article as:
Gatley J. S., Volkow D. N., Wang J. G.-, Fowler S. J., Logan J., Ding S. Y.- and Gerasimov M., PET Imaging in Clinical Drug Abuse Research, Current Pharmaceutical Design 2005; 11 (25) . https://dx.doi.org/10.2174/138161205774424717
DOI https://dx.doi.org/10.2174/138161205774424717 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Editorial [Hot Topic: Ion Channels: Applications in Ion Channel Drug Discovery(Guest Editor: Douglas S. Krafte)]
Combinatorial Chemistry & High Throughput Screening Assessing Structure, Function and Druggability of Major Inhibitory Neurotransmitter γ-Aminobutyrate Symporter Subtypes
Current Medicinal Chemistry Therapeutic Hypothermia in Brain Injuries and Related Diseases
Recent Patents on Inflammation & Allergy Drug Discovery The Contribution of DTI in Determining the Relationship of Epilepsy and Brain Lesions in Children with Tuberous Sclerosis
Current Medical Imaging Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Voltage Gated ion Channels: Targets for Anticonvulsant Drugs
Current Topics in Medicinal Chemistry Neuroprotection by Natural Polyphenols: Molecular Mechanisms
Central Nervous System Agents in Medicinal Chemistry Neuroimaging methods in Epilepsy of Temporal Origin
Current Medical Imaging Functional Characterisation of Homomeric Ionotropic Glutamate Receptors GluR1-GluR6 in a Fluorescence-Based High Throughput Screening Assay
Combinatorial Chemistry & High Throughput Screening subject Index To Volume 2
Current Genomics Stereoselective Interactions Between Local Anesthetics and Cardiac K+ Channels
Drug Design Reviews - Online (Discontinued) GABAA Receptors, Anesthetics and Anticonvulsants in Brain Development
CNS & Neurological Disorders - Drug Targets Upregulated Long Non-coding RNA ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic Cerebral Injury
Current Pharmaceutical Design Propitious Profile of Peppery Piperine
Current Molecular Pharmacology CNS Drug Delivery Systems: Novel Approaches
Recent Patents on Drug Delivery & Formulation Role of Kynurenines in the Central and Peripherial Nervous Systems
Current Neurovascular Research An Insight into the New Anticonvulsant Agents
Current Topics in Medicinal Chemistry Tools in the Design of Therapeutic Drugs for CNS Disorders: An up-to-date Review
Current Molecular Pharmacology Glutathione-Related Factors and Oxidative Stress in Autism, A Review
Current Medicinal Chemistry